← Eichor
Study identifier: NCT06850480 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis

Condition: Reflux Esophagitis (RE)  ·  Sponsor: Livzon Pharmaceutical Group Inc.

PhasePhase 3
Planned participants356
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.

This description comes directly from the study's public registry record.

Talk to the study team

Shutian Zhang, Dr.  ·  +86-010-63016616  ·  zhangst@ccmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Friendship Hospital, Capital Medical UniverstiyBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06850480